Evidence map›Paper›PMID 36381077›Full record

ArticleJournal of medical biochemistry2022

Antiphospholipid antibodies in healthy Serbian middle-aged subjects: Preliminary data.

Mirjana B Bećarević, Snežana Jovičić, Svetlana D Ignjatović, Duško Mirković

Open access · diamondAbstract read
In one paragraph

Article in Journal of medical biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mirjana B BećarevićUniversity of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad.
Snežana JovičićUniversity of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade.
Svetlana D IgnjatovićUniversity of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade.
Duško MirkovićUniversity of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry, Belgrade.
University of Belgrade · RSUniversity of Novi Sad · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The investigation of the prevalence of the IgG and the IgM isotypes of anticardiolipin (aCL) and antib2glycoprotein I (ab2gpI) Abs in healthy Serbian middleaged subjects was the main goal of our study. In addition, we analyzed the potential associations of above-mentioned Abs with serum proteins and lipids/lipoproteins. Methods: Forty healthy subjects were included in our study. Obesity (BMI 30 kg/m2) was present in 8/40 (20%) subjects. Titers of analyzed Abs were measured by ELISA. Results: The prevalence of IgG and IgM ab2gpI Abs was 5% and 12.5%, respectively, while the prevalence of IgM aCL was 10%. The IgG ab2gpI Abs were significantly different between subjects with normal triglycerides levels and those with hypertriglyceridemia (Mann-Whitney, P = 0.014). The significant difference in hsCRP concentrations was observed between subjects with the increased levels of the IgM isotype of aCL Abs and those with normal IgM aCL values (Mann-Whitney, P = 0.028). Conclusions: Dyslipidemia and BMI ≥30 were associated with aPL Abs and therefore, the correction of BMI and lipid status might be beneficial in reduction or elimination of predisposing factors that might trigger thrombotic events in otherwise healthy middle-aged subjects. Larger national study is necessary to confirm our findings.

Indexed as

antiphospholipid antibodiesapolipoproteinscomplement componentsC-reactive proteinhaptoglobinserum amylod A

Identifiers

PMID36381077
PMCPMC9618332
OpenAlexW4210667845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.